| 摘要 |
Pharmaceutical composition, useful for the treatment of hypercholesteremia in mammals, especially humans, comprising (a) a cholesterol synthesis inhibitor acting at the HMG-CoA reductase level with an EO50 less than 10<-><6>, such as a 6-[2-(8-substituted-2-methyl-1,2,6,7,8,8a -hexahydro-1-naphthyl) ethyl]-4-hydroxy-4, 5- dihydro-2-pyrone or a 4R trans-6-phenyl-E-4- hydroxytetrahydropyran-2-one in which E is a bond, a C1-3 alkylene or-CH=CH-and (b) a non-toxic anion exchange resin in the weight ratio of 1:0.08 to 1:15,000. The resin preferably is a styrene-divinylbenzene copolymer containing quaternary ammonium groups. When present in the indicated weight ratios, synergism exists between the cholesterol synthesis innibitor and the anion exchange resin. The components can be present separately for separate dosages or, preferably, as a unitary combination. The effects of treatments with compound II (Compactin) and with cholestyramine, separately and in combination, are illustrated by figure 1.
|
